Information

Back Number of 2026

• NEW
  30 Oct.

  Notice of Change in the Date of Execution of the Share Transfer Concerning the Acquisition of Shares of Tanabe Pharma Factory Co., Ltd. from Tanabe Pharma Corporation (Making It a Wholly Owned Subsidiary)

• NEW
  1 Oct.

  Updated IR Calendar

• 2 Sep.

  Briefing Script and Q&A Summary of financial results meeting for the first quarter of the year ending March 31, 2027

• 1 Sep.

  Closed Minamiosaka Branch

• 18 Aug.

  Briefing Script and Q&A Summary of briefing on the Acquisition of Shares of Tanabe Pharma Factory Co., Ltd. and Transfer of Manufacturing and Marketing Approvals

• 17 Aug.

  Towa Receives Manufacturing and Marketing Approval for Generic Drugs

• 6 Aug.

  FY2026(1st quarter) Supplementary Material of Financial Results

• 6 Aug.

  Consolidated Financial Results for the Three Months Ended June 30, 2026(Based on Japanese GAAP)

• 31 Jul.

  Notice of Completion of Payment for the Issuance of 1st Series Class A Preferred Shares through Third-Party Allotment and Taking Effect of Reduction of Amounts of Share Capital and Legal Capital Surplus

• 29 Jul.

  Acquisition of Shares of Tanabe Pharma Factory Co., Ltd. and Transfer of Manufacturing and Marketing Approvals

• 10 Jul.

  Notice of Completion of Payment for Disposal of Treasury Shares as Restricted Stock Compensation

• 3 Jul.

  Notice of Acquisition of Shares of Tanabe Pharma Factory Co., Ltd. from Tanabe Pharma Corporation (Making it a Wholly Owned Subsidiary) and Transfer of Manufacturing and Marketing Approvals

• 2 Jul.

  Updated IR Calendar

• 24 Jun.

  Matters Related to Controlling Shareholders

• 24 Jun.

  Notice of Financial Results of Parent Company, etc.

• 24 Jun.

  Notice of Disposal of Treasury Shares as Restricted Stock Compensation

• 24 Jun.

  Notice of Changes in Officers

• 22 Jun.

  Updated Financial Highlight

• 11 Jun.

  Listing of Eight Ingredients and Thirteen New Products (New Generics) in the NHI Drug Price Standard

• 29 May

  Notice of the 70th Ordinary General Meeting of Shareholders

• 21 May

  Notice of Changes in Officers

• 21 May

  Notice of Issuance of Class A Preferred Shares through Third-Party Allotment, Partial Amendment of the Articles of Incorporation, and Reduction of Amounts of Share Capital and Legal Capital Surplus

• 14 May

  Consolidated Financial Results for the Year Ended March 31, 2026(Based on Japanese GAAP)

• 14 May

  FY2025 Supplementary Material of Financial Results

• 11 May

  Notice of Recognition of an Impairment Loss, Recognition of a Loss on Valuation of Shares of Subsidiaries and Associates in the Non-consolidated Financial Statements of the Company, and Revisions of Financial Forecasts

• 23 Apr.

  Toward Ensuring a Stable Supply of Off-Patent Medical Products Towa Pharmaceutical Agrees to Collaborate with Sanwa Kagaku Kenkyusho Co., Ltd., with the Aim of Establishing a Backup Production System

• 16 Apr.

  Toward Ensuring a Stable Supply of Off-Patent Medical Products*1 Towa Pharmaceutical Concludes a Basic Agreement with Adragos Pharma Kawagoe on a Contract Manufacturing Partnership for Pharmaceuticals

• 1 Apr.

  Updated IR Calendar

• 1 Apr.

  Updated Corporate Data

• 16 Feb.

  Towa Receives Manufacturing and Marketing Approval for Generic Drugs

• 13 Feb.

  FY2025(3rd quarter) Supplementary Material of Financial Results

• 13 Feb.

  Consolidated Financial Results for the Nine Months Ended December 31, 2025(Based on Japanese GAAP)

• 21 Jan.

  Strategic collaboration between brand-name and generic drug companies Toward Ensuring a Stable Supply of Off-Patent Medicinal Products

• 5 Jan.

  Updated IR Calendar